Childhood Cancer Survival in Brunei Darussalam

Elvynna Leong1,2, Sok King Ong3, Fadzilah Jali1

  • 1Faculty of Science, Universiti Brunei Darussalam, Jln Tungku Link, Brunei Darussalam.

Insights

Childhood cancer survival rates in Brunei Darussalam are 79.4% at 1 year and 70.0% at 5 years. Survival is influenced by cancer type, age at diagnosis, and treatment period, aiding cancer control program planning.

Area of Science:

  • Pediatric Oncology
  • Cancer Epidemiology
  • Public Health

Background:

  • Childhood cancer survival rates in Brunei Darussalam are not well-established.
  • Understanding survival factors is crucial for improving outcomes in pediatric cancer patients.

Purpose of the Study:

  • To determine overall survival rates for children and adolescents (0-19 years) diagnosed with cancer in Brunei Darussalam.
  • To identify factors associated with childhood cancer survival.

Main Methods:

  • Analysis of 263 de-identified childhood cancer cases from 2002-2017 using a population-based cancer registry.
  • Kaplan-Meier method for overall survival estimation.
  • Log-rank and Cox Proportional Hazard (PH) regression analyses to identify significant survival factors.

Main Results:

  • Overall 1-, 5-, and 10-year survival rates were 79.4%, 70.0%, and 68.8%, respectively.
  • Malignant epithelial neoplasms had the highest 5-year survival (84.2%), while CNS tumors had the lowest (44.1%).
  • Lymphomas, gonadal/germ cell neoplasms, malignant epithelial neoplasms, younger age groups, and earlier diagnosis periods were associated with lower mortality hazard.

Conclusions:

  • Establishes baseline childhood cancer survival data for Brunei Darussalam.
  • Provides evidence for targeted cancer control strategies, including surveillance, screening, and treatment.
  • Aims to improve childhood cancer survival rates through informed program planning.
Abstract

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...